[Advances in immunotherapy of hematological malignancies by using chimeric antigen receptor-modified lymphocytes].

Abstract

Chimeric antigen receptors (CAR) are fusion proteins between single-chain variable fragments (scFv) from monoclonal antibodies and signaling domains of T-cells, which allow T-cells recognize specific cell-surface targets in an MHC-unrestricted fashion. The structure of CAR has changed over time, from first generation CAR (scFv + signaling moiety) to 2 and 3… (More)
DOI: 10.7534/j.issn.1009-2137.2013.02.056

Topics

  • Presentations referencing similar topics